Mixtures and binding partners
A second active drug, a carrier, a bound metal and a receptor each have a different relationship to the peptide. The distinction matters to the result.
Companion roles
The GHK hair preparation and the KPV combination both contain more than one active ingredient. Copper belongs to the GHK-Cu complex itself. Albumin, by contrast, is a blood protein the metabolic medicines bind after entering circulation. The GIP and GLP-1 receptors are targets for tirzepatide's activity.
| Relationship | Example | Research setting |
|---|---|---|
| Metal complex | GHK with copper | Skin and cell studies |
| Active mixture | GHK with another ingredient | Small human hair trial |
| Protected cargo | KPV in particles and gel | Mouse colitis |
| Drug combination | KPV with an immunosuppressant | Mouse colitis |
| Blood-protein binding | Semaglutide and albumin | Clinical pharmacology |
| Dual receptor action | Tirzepatide at GIP and GLP-1 | Human trial programme |
The GHK hair study, KPV carrier experiment and KPV combination study give the first comparisons concrete form. Clinical reviews discuss semaglutide and tirzepatide. I prefer these comparisons with each relationship intact. Grouping them as combinations would hide distinctions the chemistry depends on.
Carriers, combinations and finished products
A hair trial used GHK combined with another ingredient, while a KPV experiment paired the peptide with an immunosuppressant. The outcomes belong to those mixtures. In the KPV case, the targeted preparation itself was part of the innovation.
The same attention to preparations applies to the approved medicines. A trial tests the finished product and assigned treatment conditions. Compounded medicines are not FDA-approved, and an unchecked preparation inherits neither the quality nor the evidence of a trial product merely by carrying the same compound name.
The biggest unresolved delivery questions here concern systemic GHK-Cu and human KPV. Validated human pharmacokinetics and dependable clinical safety evidence are missing for those uses. Their arrival at a tissue cannot simply be assumed from a cell experiment.
Separate measurements in people
The small topical studies gathered in the GHK review concern skin appearance and supporting proteins. KPV's colitis findings concern mice. That distinction remains even where both lines of work use the language of repair.
Semaglutide has trials measuring body weight, cardiovascular events and a kidney-disease composite including cardiovascular deaths in separate populations. Tirzepatide has both placebo-controlled weight results and direct weight comparisons with semaglutide.
The molecular partnerships drew me in. The later trials add an essential demand: count what happens to people, including adverse effects. The semaglutide safety discussion and tirzepatide safety discussion describe the digestive, gallbladder and other concerns alongside their benefits.